Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Public ClinicalTrials.gov record NCT00088855. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Bortezomib (PS-341) and Pegylated Liposomal Doxorubicin as Initial Therapy for Adult Patients With Symptomatic Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies the side effects and how well bortezomib and pegylated liposomal doxorubicin hydrochloride work in treating patients multiple myeloma that are experiencing symptoms and have not received prior treatment. Bortezomib and pegylated liposomal doxorubicin hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study identification
- NCT ID
- NCT00088855
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- Bortezomib Drug
- Laboratory Biomarker Analysis Other
- Pegylated Liposomal Doxorubicin Hydrochloride Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 15, 2004 (Actual)
- Primary completion
- Oct 31, 2006 (Actual)
- Completion
- Jan 8, 2008 (Actual)
- Last update posted
- Sep 23, 2019
2004 – 2008
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palo Alto Medical Foundation-Camino Division | Mountain View | California | 94040 | — |
| Christiana Care Health System-Christiana Hospital | Newark | Delaware | 19718 | — |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| MedStar Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Jupiter Medical Center | Jupiter | Florida | 33458 | — |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| AdventHealth Orlando | Orlando | Florida | 32803 | — |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| Kansas City NCI Community Oncology Research Program | Prairie Village | Kansas | 66208 | — |
| Walter Reed National Military Medical Center | Bethesda | Maryland | 20889-5600 | — |
| Minneapolis VA Medical Center | Minneapolis | Minnesota | 55417 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Missouri Baptist Medical Center | St Louis | Missouri | 63131 | — |
| Center for Cancer Care and Research | St Louis | Missouri | 63141 | — |
| Frisbie Hospital | Rochester | New Hampshire | 03867 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| Novant Health Presbyterian Medical Center | Charlotte | North Carolina | 28204 | — |
| Lenoir Memorial Hospital | Kinston | North Carolina | 28501 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| Greenville Health System Cancer Institute-Eastside | Greenville | South Carolina | 29615 | — |
| Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners | Vermont | 05602 | — |
| University of Vermont and State Agricultural College | Burlington | Vermont | 05405 | — |
| Danville Regional Medical Center | Danville | Virginia | 24541 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00088855, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 23, 2019 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00088855 live on ClinicalTrials.gov.